Beth Seidenberg

Beth Seidenberg


    A longtime life sciences investor, founding managing director of Westlake Village BioPartners, and a partner at Kleiner Perkins, Dr. Seidenberg has incubated and invested in more than 20 healthcare companies during her career, including but not limited to ARMO, Arresto, Arsenal Biosciences, Atara Biotherapeutics, Cell Design Labs, Epizyme, Flexus, iPerian, Kyverna Therapeutics, TESARO, RAPT, True North, Livongo, and Progyny.

    Dr. Seidenberg believes the pace and quality of innovation has hit an inflection point, providing the opportunity to turn the next big technologies into products and companies that benefit human health. She has a demonstrated ability to identify and accelerate meaningful molecules through development. Her expertise is grounded in her significant senior-level industry experience with leadership roles at Amgen, Bristol-Myers Squibb and Merck Research Laboratories.

    Prior to life science investing, Dr. Seidenberg’s career focused on developing new treatments for AIDS, arthritis, asthma, cancer and psoriasis, cardiovascular, metabolic, neurological and renal disorders for over 20 years. During that time, she introduced 10 innovative products to market.

    Dr. Seidenberg holds a Bachelor of Science degree in biology and anthropology from Barnard College and attended medical school at the University of Miami School of Medicine. She completed her medical residency at Johns Hopkins University and George Washington University, and Fellowship at the National Institutes of Health.


    Current

    Alumni

    ARMO BioSciences (Eli Lilly acquired)
    Arresto Biosciences (Gilead Sciences acquired)
    Breathe Technologies (Hill-Rom acquired)
    Cell Design Labs (Gilead Sciences acquired)
    iPierian (Bristol-Myers Squibb acquired)
    Progyny PGNY:NASDAQ
    True North Therapeutics (Bioverativ acquired)

    Current

    Alumni

    ARMO BioSciences (Eli Lilly acquired)
    Arresto Biosciences (Gilead Sciences acquired)
    Breathe Technologies (Hill-Rom acquired)
    Cell Design Labs (Gilead Sciences acquired)
    iPierian (Bristol-Myers Squibb acquired)
    Progyny PGNY:NASDAQ
    True North Therapeutics (Bioverativ acquired)